GRI Bio, Inc.

GRI · Nasdaq · United States

Share price · GRI

$1.27-0.44 (-25.73%) 3M

close as of 2026-11-18 · 24h delayed · vol 27K (0.6x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when GRI's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 16 Nov 2026-17.6%
  2. 6 Nov 2026+21.3%
  3. 8 Sep 2026-30.6%
  4. 4 Sep 2026+25.8%

    Nothing announced by GRI that day or the session before.

  5. 3 Sep 2026+14.5%

    Nothing announced by GRI that day or the session before.

  6. 11 Aug 2026+29.4%
  7. 10 Aug 2026+15.6%
  8. 4 Aug 2026+10.4%
  9. 26 Jun 2026-7.1%
  10. 18 Jun 2026-19.0%

Share of unusual movement by asset

For each asset, the share of GRI's own-move activity since 3 Sep 2025 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—0%
Sessions with no dated event—100%

No dated announcements about its assets since 3 Sep 2025.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
Showing 1 of 1 assets
Target & Modality
Preclinical / Unstaged
Type 2 NKT cells (activator)Small molecule
Systemic Lupus Erythematosus

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$0.2M$9.5M$1.5M-$1.5M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$0.4M$11M$1.6M-$1.4M operating cash flowreport ↗
2026-Q1—$0.4M$11M$2.0M-$3.7M operating cash flowreport ↗
2025-Q3—$1.8M$4.1M$3.4M-$2.3M operating cash flowreport ↗
2025-Q2—$1.9M$5.1M$2.9M-$3.2M operating cash flowreport ↗
2025-Q1—$1.6M$3.3M$3.0M-$1.7M operating cash flowreport ↗
2024-Q3—$1.1M$4.8M$2.1M-$2.3M operating cash flowreport ↗
2024-Q2—$0.9M$6.3M$2.3M-$2.1M operating cash flowreport ↗
2024-Q1—$0.9M$4.1M$1.9M-$2.2M operating cash flowreport ↗
2023-Q3—$1.2M$3.5M$2.1M-$1.3M operating cash flowreport ↗
2023-Q2—$0.9M$4.8M$6.8M$0 operating cash flowreport ↗
2023-Q1—-$0.1M$1.7M+ $0 short-term inv.$2.4M-$2.1M operating cash flowreport ↗
2022-Q3—-<$0.1M$4.7M+ $0.4M short-term inv.$1.0M-$1.9M operating cash flowreport ↗
2022-Q2—$0.3M$5.2M+ $1.8M short-term inv.$1.8M-$1.6M operating cash flowreport ↗
2022-Q1$0$1.3M$2.5M+ $2.6M short-term inv.$2.6M-$2.3M operating cash flowreport ↗
2021-Q3$0$0.2M$5.9M+ $3.3M short-term inv.$1.3M-$1.3M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—$6.8M$8.2M$3.0M-$10M operating cash flowreport ↗
View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY—$3.8M$5.0M$2.0M-$8.6M operating cash flowreport ↗
2023-FY—$3.2M$1.8M$3.3M-$9.0M operating cash flowreport ↗
2022-FY—$1.2M$3.8M+ $0 short-term inv.$1.8M-$7.1M operating cash flowreport ↗
2021-FY$0$5.2M$3.7M+ $3.8M short-term inv.$2.3M-$8.3M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-04Szekeres David Leslie · directorAward / grant (derivative)6,558——Form 4
2026-11-04Rongen Roelof · directorAward / grant (derivative)3,935——Form 4
2026-11-04SIMPSON CAMILLA V · directorAward / grant (derivative)3,935——Form 4
2026-11-04Baker David Charles · directorAward / grant (derivative)3,935——Form 4
2025-09-18Hertz Walter Marc · director, Chief Executive OfficerAward / grant (derivative)103,067——Form 4
2025-09-18Rongen Roelof · directorAward / grant (derivative)23,605——Form 4
2025-09-18Chaturvedi Vipin · Chief Scientific OfficerAward / grant (derivative)43,222——Form 4
2025-09-18SIMPSON CAMILLA V · directorAward / grant (derivative)23,605——Form 4